NCYT Stock Chart & Stats
36.95 p
-0.45 p(-1.22%)
At close: 4:00 PM EDT
36.95 p
-0.45 p(-1.22%)
Day’s Range― - ―
52-Week Range26.60 p - 86.00 p
Previous CloseN/A
Volume4.79K
Average Volume (3M)53.03K
Market Cap
£30.61M
Enterprise Value29.84 p
Total Cash (Recent Filing)£19.14M
Total Debt (Recent Filing)£10.44M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding72,588,090
10 Day Avg. Volume53,342
30 Day Avg. Volume53,028
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)1.35
P/FCF Ratio-3.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-12.27
Revenue Forecast (FY)£2.59B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthSustained growth across three consecutive half-years indicates improving commercial traction rather than an isolated revenue spike. Underlying growth of about 9% excluding Southern Cross also suggests the existing business is expanding, while broader geographic and product demand can support continued scale.
Product Innovation And Strategic PartnershipThe approved DPYD assay expands Novacyt’s clinical offering into treatment-guiding genetic testing, while the five-year Illumina agreement provides a longer-term collaboration platform. Together, they strengthen commercialization potential and broaden the company’s relevance beyond infectious-disease testing.
Meaningful Cost-reduction ProgramThe reduction in staffing and nonlabor costs provides a defined route to a lower operating base, with most benefits expected from 2027. If delivered, these savings should reduce future cash burn and improve operating leverage, allowing revenue growth to translate more effectively into earnings.
Bears Say
Persistent Structural LossesRecurring losses across multiple years show that the current revenue base has not yet covered the company’s cost structure. The latest EBITDA deficit confirms that profitability remains unresolved, limiting internally generated funding and leaving performance dependent on successful growth and restructuring execution.
Continued Cash ConsumptionMulti-year negative cash flow indicates that Novacyt remains in a cash-consuming phase rather than generating self-funded growth. Although management expects restructuring to reduce burn, ongoing losses and substantial recent cash usage could constrain investment flexibility and increase financing pressure if improvement is delayed.
Margin Pressure And Weaker RUO MixLower gross margin reduces the contribution available to absorb operating costs, while declining high-margin RUO sales weakens the revenue mix. Southern Cross dilution and reduced Primerdesign weighting explain part of the pressure, but restoring mix quality is important for achieving the targeted long-term margin above 60%.
Novacyt News
NCYT FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest share price was 26.60 p and its highest was 86.00 p in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is £30.61M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Apr 29, 2027 which is in 208 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Sep 30, 2026. The company reported -0.079 p earnings per share for the quarter.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -0.079 p in its last earnings report. Following the earnings report the stock price went down -2.098%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in GB:NCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
NCYT Company Deck
NCYT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive. Management highlighted 18% year-on-year revenue growth, three consecutive half-years of growth, broad geographic and product expansion, the Southern Cross contribution, the DPYD launch, the five-year Illumina agreement and substantial operating-cost reductions. The principal negatives were the decline in gross margin to 56%, lower RUO sales, continued EBITDA losses, cash consumption and an incomplete restructuring program. Management characterized the cost actions as on plan and said cash burn should materially decline after restructuring.View all GB:NCYT earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―